In this episode Dr Harry Gibbs, from The Alfred Hospital in Victoria and Dr Ander Cohen from Guy’s and St Thomas’ Hospital, King’s College in London, UK discuss the management of ongoing treatment with DOACs in patients with cancer. They consider the additional provoking factors in cancer patients, when it might be safe to reduce the dose, and the additional treatment challenges of maintaining efficacy in patients at increased risk of bleeding.

ELIQUIS® (apixaban)

PBS Information: Authority required (STREAMLINED) Refer to PBS Schedule for full authority information.

PBS Codes: NVAF – 4269 and DVT/Pe initial treatment – 4298 (DVT); 5098 (PE). Other PBS codes differ – please refer to PBS Schedule.

NVAF: Non-valvular atrial fibrillation; DVT: Deep vein thrombosis; PE: Pulmonary embolism.

Before prescribing, please review full ELIQUIS Product Information available from Bristol Myers Squibb Australia by calling 1800 067 567.

Please note that apixaban is contraindicated in patients with malignant neoplasms at high risk of bleeding. The efficacy and safety of apixaban for the treatment of DVT/PE in patients with active cancer is not established.

ELIQUIS Consumer Medical Information

ELIQUIS Product Information

Reference

1. Lyman GH, Carrier M, Ay C et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5: 927-74.

 t360 is an educational program supported by Bristol Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, Level 2, 4 Nexus Court, Mulgrave VIC 3170 and Pfizer Australia Pty Ltd, ABN 50 008 422 348, 151 Clarence Street, Level 15–18, Sydney NSW 2000, and developed by Elixir Healthcare Education Pty Limited, ABN 36 092 185 665, Level 32, 101 Miller Street, North Sydney NSW 2060. ©Copyright 2022 Bristol Myers Squibb–Pfizer Alliance and Elixir Healthcare Education Pty Limited. PP-ELI-AUS-1091.